Table 1:
Study Namea | Institution | Patient Enrollment Settingsb | Target Enrollment Populations (Sub-populations)b | Key Outcomes |
---|---|---|---|---|
CHARM | Kaiser Permanente Northwest |
Outpatient primary care clinics from two
health systems: Kaiser Permanente Northwest (Portland, Oregon), and Denver Health (a system of Federally Qualified Health Centers in Denver, Colorado) |
Adults (18–49 years) at risk for
hereditary cancer; (Racial/ethnic minority, low income, low health literacy, Medicaid/ Medicare or uninsured, Spanish speaking) |
Assesses the utility of clinical exome sequencing and how it affects care in diverse populations of adults at risk for hereditary cancer syndromes. |
ClinSeq | NIH / NHGRIc | National Institutes of Health Clinical Center (Bethesda, Maryland) | Adults, no specific phenotype; (African American, Afro-Caribbean, African) |
Conducts genetic sequencing amongst healthy volunteers in order to study the impact of returning their individual genetic results and to build a resource for genotypedrive research. |
KidsCanSeq | Baylor College of Medicine | Academic and non-academic medical centers,
outpatient clinics in Texas: Texas Children’s Hospital, MD Anderson Cancer Center (Houston); University of Texas Health Science Center at San Antonio, Children’s Hospital of San Antonio (San Antonio); Cook Children’s (Fort Worth); Vannie Cook Children’s Clinic (McAllen) |
Children with cancer and their parents;
(Medically underserved, Hispanic/Latino, African American, Asian, Spanish speaking) |
Studies the utility of genome-scale testing, compared with more targeted methods, in diverse pediatric cancer patient populations and diverse health care settings in Texas. |
NCGENES2 | University of North Carolina at Chapel Hill | Outpatient pediatric genetic and neurology clinics at academic medical centers; community hospital in North Carolina: University of North Carolina Chapel Hill (Chapel Hill), Mission Health (Asheville), East Carolina University (Greenville) | Children (< 16 years) and caregivers presenting as new patients with suspected genetic conditions (developmental disabilities, dysmorphology, neuromuscular disorders); (African American, Hispanic/Latino, Medicaid or uninsured) | Assesses the utility of clinical exome sequencing compared to standard of care testing in diverse pediatric populations presenting for initial genetic evaluation. Also assesses the impact of pre-clinic preparatory materials on measures of caregiver-provider engagement and care. |
NYCKidsSeq | Icahn School of Medicine at Mount Sinai & Montefiore Medical Center | Academic medical centers, private practice in
New York City, New York: The Mount Sinai Hospital, Mount Sinai Doctors Faculty Practice, Mount Sinai Kravis Children’s Hospital, Mount Sinai West Hospital (Manhattan); Montefiore Medical Center, The Children’s Hospital at Montefiore (Bronx) |
Children (ages 0–21) with suspected neurologic, immunologic, and cardiac genetic conditions; (African American, Hispanic/Latino, Medicaid, Spanish-speaking) | Assesses the clinical and economic utility for use of genomic medicine for underserved children. Also assesses family understanding and satisfaction. |
P3EGS | University of California, San Francisco | Academic medical center, outpatient clinics, neonatal intensive care unit in pediatric intensive care unit and community hospital in California: UCSF Benioff Children’s Hospital Mission Bay, UCSF Fetal Treatment Center, Zuckerberg San Francisco General Hospital, (San Francisco); UCSF Benioff Children’s Hospital Oakland (Oakland); Fresno Community Health Center (Fresno) | Infants and children with severe developmental
disorders, with or without congenital anomalies (pediatric); parents
whose fetus has a structural anomaly (prenatal); (Underserved by census tract, Medicaid, Asian, Hispanic/Latino, African American) |
Assesses the utility of whole exome sequencing as a tool for diagnosing infants and children with serious developmental disorders. Also assesses providing genetic information to parents when a prenatal study reveals a fetus with a structural anomaly. |
SouthSeq | HudsonAlpha Institute for Biotechnology | Academic medical center and community neonatal
intensive care units, academic maternal fetal medicine outpatient
clinics; Children’s Hospital of New Orleans (New Orleans,
Louisiana); University of Alabama at Birmingham (Birmingham, Alabama;
University of Louisville (Louisville, Kentucky; University of Mississippi Medical Center, Woman’s Hospital (Jackson, Mississippi) |
Newborns with suspected genetic
conditions; (African American, underserved, rural) |
Performs whole-genome sequencing on newborns suspected to have genetic disorders. Assesses return of results mechanisms to expand access to genetic testing to diverse, especially historically underserved, communities. |
All projects have study materials (including consent forms, education materials, and surveys) available in both English and Spanish, some of which is publicly available at https://cser-consortium.org/cser-research-materials.
ClinSeq completed enrollment at the start of the extramural studies and thus did not assess stakeholder engagement-related variables as in other CSER projects.